Abstract

Research Article

The Immunitary role in chronic prostatitis and growth factors as promoter of BPH

Mauro luisetto*, Behzad Nili-Ahmadabadi, Ghulam Rasool Mashori, Ram Kumar Sahu, Farhan Ahmad Khan, Cabianca luca and Heba Nasser

Published: 25 April, 2018 | Volume 2 - Issue 1 | Pages: 001-013

In the actual medical therapy of BPH, we can see: antibiotics, alpha blockers, 5-ARI, fitotherapeutics/natural products (Serenoa repens) with different which display clinical activities and other molecules such as FANS (local or systemic dosage forms) cortisones and others. Relationship between immune systems and chronic prostatitis are strictly involved in BPH progression. A vicious cycle that involve chronic flogosis, tissue remodeling, grow factors, inhibition of apoptosis, and other phenomena. Observing BPH pathogenesis under an immunologic point of view make possible to search new pharmacological strategies, to improve actual therapy.

The aim of this work is to observe some relevant literature in our opinion related the management of BHP and its progression under a pharmaceutical and immunological point of view. A deep knowledge in the pharmaceutical properties of some molecules (antimicrobials, anti-phlogosis agents, Anti-androgenic agents, alpha blockers, 5-ARI and other treatments, techniques, interventions or instruments) can help the physicians to pick the right choice.

Read Full Article HTML DOI: 10.29328/journal.icci.1001003 Cite this Article Read Full Article PDF

Keywords:

BPH; Medicinal chemistry; Clinical pharmacy; Drug design; Drug delivery

References

  1. Luisetto M, Nili-Ahmadabad B, Mashori GR. Relapses and Recurrent Chronic Bacteria Prostatitis - Biofilm Related, A Case Report. J Pharmacology Clin Res. 2017; 4. Ref.: https://goo.gl/zJ68rs
  2. Vela NR, Garcia CJV, Barat A, Manzarbeitia F, Lopez FA. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003; 44: 549-555. Ref.: https://goo.gl/r9zpij
  3. Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, et al. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012; 110: 301-307. Ref.: https://goo.gl/1xXvHX
  4. Ficarra V. Chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH)?. BJU Int. 2013; 112: 421-422. Ref.: https://goo.gl/1FRfQC
  5. Choi H, Chang YS, Park BH, Ko DH, Kim JB, et al. Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor. Korean J Androl. 2012; 30: 45-51. Ref.: https://goo.gl/zy8Uq5
  6. Luisetto M, Nili-Ahmadabadi B. Chronic Prostatitis: The Clinical Pharmacist Role and New Delivery Systems. J Bioanalysis Biomedicine. 2017; 09. Ref.: https://goo.gl/fuqawC
  7. Skeldon SC, Macdonald EM, Law MR, Huang A, Paterson JM, et al. The Cardiovascular Safety of Dutasteride. J Urol. 2017; 197: 1309-1314. Ref.: https://goo.gl/S6rxki
  8. Loke YK, Ho R, Smith M, Wong O, Sandhu M, et al. Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride. J Clin Pharm Ther. 2013; 38: 405-415. Ref.: https://goo.gl/kkNHR4
  9. Ravish IR, Nerli RB, Amarkhed SS. Finasteride to Evaluate the Efficacy of Dutasteride in the Management of Patients with Lower Urinary Tract Symptoms and Enlarged Prostate, Arch Androl. 2007; 53: 17-20. Ref.: https://goo.gl/8VQz3b
  10. Toren P, Margel D, Kulkarni G, Finelli A, Zlotta A, et al. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. BMJ. 2013; 15: 345. Ref.: https://goo.gl/xdXttB
  11. Liptay S, Bachem M, Häcker G, Adler G, Debatin KM, et al. Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol. 1999; 128: 1361-1369. Ref.: https://goo.gl/3xXVxa
  12. Perletti G, Skerk V, Magri V, Markotic A, Mazzoli S, et al. Macrolides for the treatment of chronic bacterial prostatitis: an effective application of their unique pharmacokinetic and pharmacodynamic profile (Review). Mol Med Rep. 2011; 4: 1035-1044. Ref.: https://goo.gl/kXsXon
  13. Ikeuchi T, Ueno M, Yogi S, Hasegawa K, Sasaki H, et al. Clinical studies on chronic prostatitis and prostatitis-like syndrome. (5) Evaluation of prostatitis complicated by anal disease. Hinyokika Kiyo. 1991; 37: 1677-1682. Ref.: https://goo.gl/VwWCJe
  14. Takechi S, Yokoyama M, Tanji N, Nishio S, Araki N. Nonbacterial prostatitis caused by partial urethral obstruction in the rat. Urol Res. 1999; 27: 346-350. Ref.: https://goo.gl/ZT6whzw
  15. Wilhelm EA, Jesse CR, Nogueira CW, Savegnago L. Introduction of trifl uoromethyl group into diphenyl diselenide molecule alters its toxicity and protective effect against damage induced by 2-nitropropane in rats. Exp Toxicol Pathol. 2009; 61: 197-203. Ref.: https://goo.gl/VUjWir

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Similar Articles

  • The Immunitary role in chronic prostatitis and growth factors as promoter of BPH
    Mauro luisetto*, Behzad Nili-Ahmadabadi, Ghulam Rasool Mashori, Ram Kumar Sahu, Farhan Ahmad Khan, Cabianca luca and Heba Nasser Mauro luisetto*,Behzad Nili-Ahmadabadi,Ghulam Rasool Mashori,Ram Kumar Sahu,Farhan Ahmad Khan,Cabianca luca,Heba Nasser. The Immunitary role in chronic prostatitis and growth factors as promoter of BPH. . 2018 doi: 10.29328/journal.icci.1001003; 2: 001-013

Recently Viewed

Read More

Most Viewed

Read More